Company Search:
Advanced Search
Sponsored Links
Kancera AB Company Snapshot
Kancera AB operates in the Medicinals and botanicals sector. In addition to historical fundamental analyses, the complete report available to purchase compares Kancera AB with three other pharmaceutical manufacturers in Europe: Infant Bacterial Therapeutics AB (2017 sales of 238,000.00 Swedish Kronor [US$26,444.18 ] ), Bone Therapeutics SA of Belgium (41,000.00 Euro [US$46,750.25 ] ), and NUTEX Investments Plc which is based in Hungary (8.76 million Hungarian Forints [US$31,010.40 ] ).

Sales Analysis. Kancera AB reported sales of SEK 376,000.00 (US$41.78 thousand) for the year ending December of 2017. This represents an increase of 22.1% versus 2016, when the company's sales were SEK 308,000.00 .
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Kancera AB
  Stock Performance Chart for Kancera AB
  Stock Data: Recent Stock Performance:
  Current Price (1/18/2019): 1.35
(Figures in Swedish Kronor)
1 Week 5.6%   13 Weeks 50.0%  
4 Weeks 53.4%   52 Weeks -29.4%  
Kancera AB Key Data:
  Ticker: KAN Country: Sweden
  Exchanges: STO Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Medicinals & Botanicals
  2017 Sales 376,000
(Year Ending Jan 2018).
Employees: 13
  Currency: Swedish Kronor Market Cap: 257,232,904
  Fiscal Yr Ends: December Shares Outstanding: 190,542,892
  Share Type: AKTIER Closely Held Shares: N/A
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.